Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amcad BiomedROCO:4188 +1.11%47 PS Ratio is 21.16 as of Aug. 16, 2026, which is 4% above its 10-year median of 20.43. GuruFocus rates ROCO:4188 with a GF Score™ of 47/100 and a GF Value™ of NT$9.61 (Fairly Valued). The stock has 5 warning signs investors should review. Among 803 Medical Devices & Instruments companies, Amcad Biomed ranks worse than 91.16% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Amcad Biomed's share price is NT$10.05.
Amcad Biomed's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was NT$0.48. Hence, Amcad Biomed's PS Ratio for today is 21.16.
Good Sign:
Amcad Biomed Corp stock PS Ratio (=21.16) is close to 1-year low of 19.89.
The historical rank and industry rank for Amcad Biomed's PS Ratio or its related term are showing as below:
ROCO:4188'
s PS Ratio Range Over the Past 10 Years
Min: 7.78 Med: 20.43 Max: 373.62
Current: 21.16
During the past 13 years, Amcad Biomed's highest PS Ratio was 373.62. The lowest was 7.78. And the median was 20.43.
ROCO:4188's PS Ratio is ranked worse than 91.16% of 803
companies
in the Medical Devices & Instruments industry
Industry Median: 3.01
vs ROCO:4188: 21.16
Amcad Biomed Corp revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Amcad Biomed was -45.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -24.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -15.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 36.70% per year.
During the past 13 years, Amcad Biomed's highest 3-Year average Revenue per Share Growth Rate was 664.00% per year. The lowest was -54.60% per year. And the median was 1.40% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Amcad Biomed PS Ratio Related Terms
Amcad Biomed PS Ratio Historical Data
* Premium members only.
The historical data trend for Amcad Biomed's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Amcad Biomed's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amcad Biomed PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's PS Ratio distribution charts can be found below:
* The bar in red indicates where Amcad Biomed's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Amcad Biomed's PS Ratio for today is calculated as
Amcad Biomed's Share Price of today is NT$10.05. Amcad Biomed's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.48.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Amcad Biomed (ROCO:4188) has a PS Ratio of 21.16 as of Aug. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Amcad Biomed and its competitors. This is near median its historical median of 20.43. Over the past decade, Amcad Biomed's PS Ratio has ranged from 7.78 to 373.62. According to the industry distribution chart, Amcad Biomed ranks #732 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 91.2%.
Is Amcad Biomed's PS Ratio too high?
Amcad Biomed's current PS Ratio of 21.16 is near median its 10-year median of 20.43. Over the past 10 years, this metric has ranged from a low of 7.78 to a high of 373.62. The Medical Devices & Instruments industry median PS Ratio is 3.01. Amcad Biomed's value of 21.16 is 603% above this industry median. Based on the distribution chart, Amcad Biomed ranks #732 out of 803 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Amcad Biomed has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Amcad Biomed ranks #732 out of 803 companies for PS Ratio. This places Amcad Biomed in the lower half of its industry. The industry median PS Ratio is 3.01. Amcad Biomed's value of 21.16 is 603% above this benchmark. Historically, Amcad Biomed's own PS Ratio has ranged from 7.78 to 373.62 over the past decade. While the company's 10-year median is 20.43 vs. the industry median of 3.01, Amcad Biomed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 3.01, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amcad Biomed's current PS Ratio of 21.16 is 603% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Amcad Biomed and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 3.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amcad Biomed's current PS Ratio is 21.16, which is near median its own 10-year median of 20.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Fairly Valued. The stock's GF Value™ is NT$9.61, compared to a current price of NT$10.05 — trading 4.6% above its estimated fair value. The current PS Ratio is 21.16, which is near median its 10-year median of 20.43 and 603% above the Medical Devices & Instruments industry median of 3.01. Amcad Biomed's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current PS Ratio is 21.16 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amcad Biomed (ROCO:4188) Overvalued in 2026?
Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued.
The current stock price of NT$10.05 is trading 4.6% above its estimated GF Value™ of NT$9.61.
GuruFocus considers Amcad Biomed to be Fairly Valued.
Key valuation signals for ROCO:4188:
PS Ratio: 21.16 (near median its 10-year median of 20.43)
GF Value™: NT$9.61 vs. price of NT$10.05 (4.6% above fair value)
Industry Position: 603% above the Medical Devices & Instruments median (#732 of 803)
No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
47GF Score
Get the complete analysis for ROCO:4188
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4188 has been successfully added to your 
